Lung cancer treatment in elderly patients

被引：0

作者：

Bréchot, Jeanne-Marie ^{[1
]}

Pailler, Marie ^{[1
]}

Morére, Jean-François ^{[1
]}

机构：

[1] Univ Paris 13, Hop Avicenne, Med Oncol Serv, F-93009 Bobigny, France

来源：

BULLETIN DU CANCER | 2007年 / 94卷 / 7-8期

关键词：

non-small cell lung carcinoma; small cell lung carcinoma; treatment; elderly; elderly assessment;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment of an elderly patient with a bronchial carcinoma is a daily challenge for the physician, because of the high incidence of lung carcinoma and a population getting older. The treatment has to be adapted, after geriatric assessment and evaluation of comorbidities, iatrogenic complications being more frequent and more severe in these patients. At the opposite, these patients are to often under-treated This article will update the therapeutic strategy for non-small cell and small-cell lung carcinoma in the elderly.

引用

页码：652 / 657

页数：6

共 47 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2] Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: Results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis - A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study [J].

Ardizzoni, A ;

Favaretto, A ;

Boni, L ;

Baldini, E ;

Castiglioni, F ;

Antonelli, P ;

Pari, F ;

Tibaldi, C ;

Altieri, AM ;

Barbera, S ;

Cacciani, G ;

Raimondi, M ;

Tixi, L ;

Stefani, M ;

Monfardini, S ;

Antilli, A ;

Rosso, R ;

Paccagnella, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :569-575

[3] Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission [J].

Aupérin, A ;

Arriagada, R ;

Pignon, JP ;

Le Péchoux, C ;

Gregor, A ;

Stephens, RJ ;

Kristjansen, PEG ;

Johnson, BE ;

Ueoka, H ;

Wagner, H ;

Aisner, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :476-484

[4]

Balducci L, 2000, Oncologist, V5, P224, DOI 10.1634/theoncologist.5-3-224

[5]

Balducci Lodovico, 2003, J Support Oncol, V1, P30

[6]

Blanchon F, 2002, REV MAL RESPIR, V19, P727

[7]

BOSSARD N, 2007, SURV PATIENTS ATTEIN

[8]

CHERIECHALLINE L, 2003, EVOLUTION INCIDENCE

[9] Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].

De Ruysscher, D ;

Pijls-Johannesma, M ;

Bentzen, SM ;

Minken, A ;

Wanders, R ;

Lutgens, L ;

Hochstenbag, M ;

Boersma, L ;

Wouters, B ;

Lammering, G ;

Vansteenkiste, J ;

Lambin, P .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1057-1063

[10] Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer [J].

Eckardt, JR ;

von Pawel, J ;

Papai, Z ;

Tomova, A ;

Tzekova, V ;

Crofts, TE ;

Brannon, S ;

Wissel, P ;

Ross, G .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2044-2051

← 1 2 3 4 5 →